These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 24205707)
1. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan]. Kamijo-Ikemori A; Ichikawa D; Matsui K; Yokoyama T; Sugaya T; Kimura K Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707 [TBL] [Abstract][Full Text] [Related]
2. [L-type fatty acid binding protein (L-FABP) and kidney disease]. Kamijo-Ikemori A; Sugaya T; Kimura K Rinsho Byori; 2014 Feb; 62(2):163-70. PubMed ID: 24800492 [TBL] [Abstract][Full Text] [Related]
5. Urinary fatty acid binding protein in renal disease. Kamijo-Ikemori A; Sugaya T; Kimura K Clin Chim Acta; 2006 Dec; 374(1-2):1-7. PubMed ID: 16860300 [TBL] [Abstract][Full Text] [Related]
6. Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury. Manabe K; Kamihata H; Motohiro M; Senoo T; Yoshida S; Iwasaka T Eur J Clin Invest; 2012 May; 42(5):557-63. PubMed ID: 22070248 [TBL] [Abstract][Full Text] [Related]
7. Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care. Doi K; Noiri E; Sugaya T Curr Opin Crit Care; 2010 Dec; 16(6):545-9. PubMed ID: 20736829 [TBL] [Abstract][Full Text] [Related]
8. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Kamijo A; Sugaya T; Hikawa A; Okada M; Okumura F; Yamanouchi M; Honda A; Okabe M; Fujino T; Hirata Y; Omata M; Kaneko R; Fujii H; Fukamizu A; Kimura K Am J Pathol; 2004 Oct; 165(4):1243-55. PubMed ID: 15466390 [TBL] [Abstract][Full Text] [Related]
9. Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Kamijo-Ikemori A; Sugaya T; Matsui K; Yokoyama T; Kimura K Nephrology (Carlton); 2011 Aug; 16(6):539-44. PubMed ID: 21504508 [TBL] [Abstract][Full Text] [Related]
10. Renal L-type fatty acid--binding protein in acute ischemic injury. Yamamoto T; Noiri E; Ono Y; Doi K; Negishi K; Kamijo A; Kimura K; Fujita T; Kinukawa T; Taniguchi H; Nakamura K; Goto M; Shinozaki N; Ohshima S; Sugaya T J Am Soc Nephrol; 2007 Nov; 18(11):2894-902. PubMed ID: 17942962 [TBL] [Abstract][Full Text] [Related]
11. Fatty acid-binding protein as marker for renal injury. Pelsers MM Scand J Clin Lab Invest Suppl; 2008; 241():73-7. PubMed ID: 18569970 [TBL] [Abstract][Full Text] [Related]
12. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Sasaki H; Kamijo-Ikemori A; Sugaya T; Yamashita K; Yokoyama T; Koike J; Sato T; Yasuda T; Kimura K Nephron Clin Pract; 2009; 112(3):c148-56. PubMed ID: 19390215 [TBL] [Abstract][Full Text] [Related]
13. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Omata M; Kimura K Mol Cell Biochem; 2006 Mar; 284(1-2):175-82. PubMed ID: 16532260 [TBL] [Abstract][Full Text] [Related]
14. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Inoue T; Node K Am J Nephrol; 2006; 26(1):82-6. PubMed ID: 16534182 [TBL] [Abstract][Full Text] [Related]
15. Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Katagiri D; Doi K; Honda K; Negishi K; Fujita T; Hisagi M; Ono M; Matsubara T; Yahagi N; Iwagami M; Ohtake T; Kobayashi S; Sugaya T; Noiri E Ann Thorac Surg; 2012 Feb; 93(2):577-83. PubMed ID: 22269724 [TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Nakamura T; Sugaya T; Node K; Ueda Y; Koide H Am J Kidney Dis; 2006 Mar; 47(3):439-44. PubMed ID: 16490622 [TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis. Mou S; Wang Q; Li J; Shi B; Ni Z Clin Chim Acta; 2012 Jan; 413(1-2):187-91. PubMed ID: 21958699 [TBL] [Abstract][Full Text] [Related]
18. Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Doi K; Noiri E; Maeda-Mamiya R; Ishii T; Negishi K; Hamasaki Y; Fujita T; Yahagi N; Koide H; Sugaya T; Nakamura T Crit Care Med; 2010 Oct; 38(10):2037-42. PubMed ID: 20657273 [TBL] [Abstract][Full Text] [Related]
19. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. Nakamura T; Sato E; Amaha M; Kawagoe Y; Maeda S; Yamagishi S J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):122-7. PubMed ID: 21946392 [TBL] [Abstract][Full Text] [Related]
20. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamagishi S Metabolism; 2011 Feb; 60(2):260-4. PubMed ID: 20189611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]